{
    "clinical_study": {
        "@rank": "308",
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on April 13, 2020",
            "link_text": "Link to the current ClinicalTrials.gov record.",
            "url": "https://clinicaltrials.gov/show/NCT04342650"
        },
        "id_info": {
            "org_study_id": "CAAE: 30504220.5.0000.0005",
            "nct_id": "NCT04342650"
        },
        "brief_title": "Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection",
        "acronym": "CloroCOVID19II",
        "official_title": "Phase IIb Study to Evaluate the Efficacy and Safety of Chloroquine Diphosphate in the Treatment of Patients With Comorbidities, Without Severe Acute Respiratory Syndrome, Under the New Coronavirus (SARS-CoV2): a Double-blind, Randomized, Placebo-controlled Clinical Trial",
        "sponsors": {
            "lead_sponsor": {
                "agency": "Funda\u00e7\u00e3o de Medicina Tropical Dr. Heitor Vieira Dourado",
                "agency_class": "Other"
            }
        },
        "source": "Funda\u00e7\u00e3o de Medicina Tropical Dr. Heitor Vieira Dourado",
        "oversight_info": {
            "has_dmc": "Yes",
            "is_fda_regulated_drug": "No",
            "is_fda_regulated_device": "No"
        },
        "brief_summary": {
            "textblock": "This is a double-blind, randomized, placebo-controlled clinical trial. A total of 210\n      individuals aged over 18 years old, without a diagnosis of severe respiratory disease, who\n      came to the study site with clinical and radiological suspicion of SARS-CoV2, will be\n      randomized into two treatment groups at a 1:1 ratio to receive a 5-day CQ diphosphate tablets\n      or placebo (tablet without active ingredient produced with the same physical\n      characteristics)."
        },
        "overall_status": "Not yet recruiting",
        "start_date": {
            "@type": "Anticipated",
            "#text": "April 2020"
        },
        "completion_date": {
            "@type": "Anticipated",
            "#text": "September 2020"
        },
        "primary_completion_date": {
            "@type": "Anticipated",
            "#text": "September 2020"
        },
        "phase": "Phase 2",
        "study_type": "Interventional",
        "has_expanded_access": "No",
        "study_design_info": {
            "allocation": "Randomized",
            "intervention_model": "Parallel Assignment",
            "primary_purpose": "Treatment",
            "masking": "Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)"
        },
        "primary_outcome": {
            "measure": "Proportion of patients with onset of severe acute respiratory syndrome (SARS)",
            "time_frame": "7 days after randomization",
            "description": "Evaluate if CQ diphosphate prevents the onset of SARS in patients on intervention group through standardized questionnaires."
        },
        "secondary_outcome": [
            {
                "measure": "Mortality rate",
                "time_frame": "after randomization, up to 28 days",
                "description": "Mortality rate between intervention and placebo group on days 7, 14, and 28 after randomization"
            },
            {
                "measure": "Number of participants in need of intensive care support",
                "time_frame": "during and after intervention, up to 28 days",
                "description": "Proportion of participants in need and duration of intensive care support after randomization"
            },
            {
                "measure": "Viral concentration",
                "time_frame": "After randomization, up to 7 days",
                "description": "Viral load change in blood and oropharyngeal swab samples"
            },
            {
                "measure": "Cumulative incidence of serious adverse events",
                "time_frame": "During and after intervention, up to 28 days",
                "description": "Incidence of serious adverse events during and after treatment"
            },
            {
                "measure": "Cumulative incidence of grade 3 and 4 adverse events",
                "time_frame": "During and after intervention, up to 28 days",
                "description": "Incidence of grade 3 and 4 adverse events during and after treatment"
            },
            {
                "measure": "Proportion of patients with discontinued treatment",
                "time_frame": "after randomization, up to 28 days",
                "description": "proportion of discontinuation or temporary suspension of treatment (for any reason)"
            },
            {
                "measure": "Incidence of cardiac lesions",
                "time_frame": "after randomization, up to 120 days",
                "description": "proportion of patients with increased levels of troponin I"
            },
            {
                "measure": "Incidence of cardiac disfunctions",
                "time_frame": "after randomization, up to 120 days",
                "description": "proportion and magnitude of QTcF interval increases higher than 500ms"
            },
            {
                "measure": "Change in respiratory capacity",
                "time_frame": "Day 120 after randomization",
                "description": "Changes measured on day 120 will be compared to baseline, through spirometry."
            }
        ],
        "number_of_arms": "2",
        "enrollment": {
            "@type": "Anticipated",
            "#text": "210"
        },
        "condition": [
            "COVID-19",
            "SARS-CoV Infection",
            "Severe Acute Respiratory Syndrome (SARS) Pneumonia",
            "Clinical Trial"
        ],
        "arm_group": [
            {
                "arm_group_label": "Intervention",
                "arm_group_type": "Active Comparator",
                "description": "CQ 450mg twice daily (3 tablets of 150mg, every 12 hours) on day 1, followed by CQ 450mg once daily (3 tablets of 150mg) from D2 to D5. Oral administration."
            },
            {
                "arm_group_label": "Placebo",
                "arm_group_type": "Placebo Comparator",
                "description": "Placebo tables of equal characteristics and duration of treatment."
            }
        ],
        "intervention": [
            {
                "intervention_type": "Drug",
                "intervention_name": "Chloroquine Diphosphate",
                "description": "150mg tablets",
                "arm_group_label": "Intervention",
                "other_name": "chloroquine"
            },
            {
                "intervention_type": "Drug",
                "intervention_name": "Placebo oral tablet",
                "description": "150mg placebo tablets",
                "arm_group_label": "Placebo"
            }
        ],
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Suspected cases of COVID-19, due to clinical and radiological data, during the\n             epidemic;\n\n          2. Adult aged 18 or over, at the time of inclusion\n\n          3. Not having severe acute respiratory syndrome (SARS), that is, not using mechanical\n             ventilation or supplemental oxygen, peripheral oxygen saturation> 94% in room air, and\n             having a respiratory rate below 24 incursions per minute.\n\n          4. Patients with comorbidities only, due to the increased risk of developing SARS\n\n        Exclusion Criteria:\n\n        1. Patients with chronic use of drugs known to prolong QTc interval."
            },
            "gender": "All",
            "minimum_age": "18 Years",
            "maximum_age": "N/A",
            "healthy_volunteers": "No"
        },
        "overall_contact": {
            "last_name": "Marcus Lacerda, MD",
            "phone": "+55 92 99114 7633",
            "email": "marcuslacerda.br@gmail.com"
        },
        "overall_contact_backup": {
            "last_name": "Fernando Val, PhD",
            "phone": "+55 92 99116 3107",
            "email": "ffaval@gmail.com"
        },
        "location": {
            "facility": {
                "name": "Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz",
                "address": {
                    "city": "Manaus",
                    "state": "Amazonas",
                    "zip": "69093-415",
                    "country": "Brazil"
                }
            }
        },
        "location_countries": {
            "country": "Brazil"
        },
        "verification_date": "April 2020",
        "study_first_submitted": "April 4, 2020",
        "study_first_submitted_qc": "April 8, 2020",
        "study_first_posted": {
            "@type": "Estimate",
            "#text": "April 13, 2020"
        },
        "last_update_submitted": "April 8, 2020",
        "last_update_submitted_qc": "April 8, 2020",
        "last_update_posted": {
            "@type": "Estimate",
            "#text": "April 13, 2020"
        },
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        },
        "condition_browse": {
            "mesh_term": [
                "Infection",
                "Severe Acute Respiratory Syndrome",
                "Coronavirus Infections",
                "Pneumonia",
                "Syndrome"
            ]
        },
        "intervention_browse": {
            "mesh_term": [
                "Chloroquine",
                "Chloroquine diphosphate"
            ]
        },
        "patient_data": {
            "sharing_ipd": "Yes",
            "ipd_description": "all patient data will be shared after study publication",
            "ipd_info_type": [
                "Study Protocol",
                "Statistical Analysis Plan (SAP)",
                "Clinical Study Report (CSR)"
            ],
            "ipd_time_frame": "after study publication",
            "ipd_access_criteria": "Upon formal request to researchers."
        }
    }
}